Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation

In this review summarizes studies presenting a propensity-matched comparative analysis evaluating alemtuzumab vs basiliximab induction in kidney transplant recipients with aligned immunological risk profiles and extended follow-up. Alemtuzumab, a potent lymphocyte-depleting agent, has therefore been widely adopted on the premise that deeper early immune suppression confers durable graft protection. Whether this assumption holds true beyond the early post-transplant period remains uncertain. A recent study demonstrates comparable rates of acute rejection between induction strategies, effectively neutralising rejection as the differentiating endpoint in contemporary practice. In contrast, clinically meaningful divergence emerges in longer-term outcomes. Alemtuzumab induction is associated with inferior graft function, higher rates of cytomegalovirus and BK viremia, increased post-transplant malignancy, and greater death-censored graft loss. These findings highlight a central paradox in transplant immunology: Strategies that achieve potent early immune suppression may incur delayed biological costs related to immune reconstitution, impaired immune surveillance, and cumulative graft injury. Collectively, the data argue for a shift away from rejection-centred metrics toward a more proportional and individualised approach to induction selection, in which long-term graft preservation and complication risk are weighed as carefully as early rejection prevention.